(Q46879963)

26 December 2017

title

Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease (English)

1 reference

26 December 2017

stem cell transplantation

main subject

1 reference

1 reference

Gopal Krishna

1

1 reference

26 December 2017

Monika Martinho

2

1 reference

26 December 2017

Pranatharthi Chandrasekar

3

1 reference

26 December 2017

Andrew J Ullmann

4

1 reference

26 December 2017

Hernando Patino

5

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

26 December 2017

published in

Pharmacotherapy

1 reference

26 December 2017

volume

27

1 reference

26 December 2017

issue

12

1 reference

26 December 2017

page(s)

1627-1636

1 reference

26 December 2017

Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Activity of posaconazole in treatment of experimental disseminated zygomycosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

The Pathophysiology of Acute Graft-versus-Host Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Diagnosis of gastrointestinal graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Adjunctive Therapy of Allergic Bronchopulmonary Aspergillosis with Itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1627

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.12.1627

1 reference

26 December 2017

PubMed ID

18041883

1 reference

26 December 2017